

 **14 January 2025**

**SUMMARY OF PRODUCT CHARACTERISTICS**

**for**

**Repevax, suspension for injection, in pre-filled syringe**

**0. D.SP.NO.**

21301

**1. NAME OF THE MEDICINAL PRODUCT**

Repevax

Diphtheria, Tetanus, Pertussis (acellular, component) and Poliomyelitis (inactivated) Vaccine (adsorbed, reduced antigen(s) content)

**2. QUALITATIVE AND QUANTITATIVE COMPOSITION**

1 dose (0.5 mL) contains:

Diphtheria Toxoid Not less than 2 IU\* (2 Lf)
Tetanus Toxoid Not less than 20 IU\* (5 Lf)
Pertussis Antigens

Pertussis Toxoid 2.5 micrograms

Filamentous Haemagglutinin 5 micrograms

Pertactin 3 micrograms

Fimbriae Types 2 and 3 5 micrograms

Poliovirus (Inactivated)\*\*

Type 1 (Mahoney) 40 D antigen units

Type 2 (MEF1) 8 D antigen units

Type 3 (Saukett) 32 D antigen units

Adsorbed on aluminium phosphate 1.5 mg (0.33 mg Al3+)

\* As lower confidence limit (p = 0.95) of activity measured according to the assay described in the European Pharmacopoeia.

\*\* Produced in Vero cells.

Repevax may contain traces of formaldehyde, glutaraldehyde, streptomycin, neomycin, polymyxin B and bovine serum albumin, which are used during the manufacturing process (see sections 4.3 and 4.4).

For the full list of excipients, see section 6.1.

**3. PHARMACEUTICAL FORM**

Suspension for injection in pre-filled syringe

Repevax appears as a uniform, cloudy, white suspension.

**4. CLINICAL PARTICULARS**

**4.1 Therapeutic indications**

Repevax (Tdap-IPV) is indicated for:

Active immunization against diphtheria,tetanus, pertussis and poliomyelitis in persons from 3 years of ageas a booster following primary immunization.

Passive protection against pertussis in early infancy following maternal immunization during pregnancy (see sections 4.2, 4.6 and 5.1).

Repevax should be used in accordance with official recommendations.

**4.2 Posology and method of administration**

Posology

A single injection of one (0.5 mL) dose is recommended in all indicated age groups.

In adolescents and adults with an unknown or incomplete diphtheria or tetanus vaccination status against diphtheria or tetanus, one dose of Repevax can be administered as part of a vaccination series to protect against pertussis and poliomyelitis and in most cases also against tetanus and diphtheria. One additional dose of a diphtheria- and tetanus- (dT) containing vaccine can be administered one month later followed by a 3rd dose of a diphtheria or dT containing vaccine 6 months after the first dose to optimize protection against disease (see section 5.1). The number and schedule of doses should be determined according to local recommendations.

Repevax can be used for repeat vaccination to boost immunity to diphtheria, tetanus and pertussis at 5 to 10 year intervals (see section 5.1).

Repevax can be used in the management of tetanus prone injuries with or without concomitant administration of Tetanus Immunoglobulin according to official recommendations.

Repevax may be administered to pregnant women during the second or third trimester to provide passive protection of infants against pertussis (see sections 4.1, 4.6 and 5.1).

Method of administration

A single injection of one dose (0.5 mL) of Repevax should be administered intramuscularly. The preferred site is into the deltoid muscle.

Repevax should not be administered into the gluteal area; intradermal or subcutaneous routes should not be used (in exceptional cases the subcutaneous route may be considered, see section 4.4).

*Precautions to be taken before handling or administering the medicinal product*

For instructions on handling of the medicinal product before administration, see section 6.6.

**4.3 Contraindications**

* Repevax should not be administered to persons with known hypersensitivity
* to diphtheria, tetanus, pertussis or poliomyelitis vaccines
* to any other component of the vaccine (see Section 6.1)
* to any residual substances carried over from manufacture (formaldehyde, glutaraldehyde, streptomycin, neomycin, polymyxin B and bovine serum albumin), which may be present in undetectable trace amounts.
* Repevax should not be administered to persons who experienced an encephalopathy of unknown origin within 7 days of previous immunization with a pertussis-containing vaccine.
* As with other vaccines, administration of Repevax should be postponed in persons suffering from an acute severe febrile illness. The presence of a minor infection (e.g., mild upper respiratory infection) is not a contraindication.

**4.4 Special warnings and precautions for use**

Repevax should not be used for primary immunization.

Regarding the interval between a booster dose of Repevax and preceding booster doses of diphtheria and/or tetanus containing vaccines, the official recommendations should generally be followed. Clinical data in adults have demonstrated that there was no clinically relevant difference in rates of adverse reactions associated with administration of Repevax as early as 4 weeks, compared to at least 5 years after a preceding dose of tetanus and diphtheria-containing vaccine.

Prior to immunization

Vaccination should be preceded by a review of the person’s medical history (in particular previous vaccinations and possible adverse events). In persons who have a history of serious or severe reaction within 48 hours of a previous injection with a vaccine containing similar components, administration of Repevax vaccine must be carefully considered.

As with all injectable vaccines, appropriate medical treatment and supervision should be readily available for immediate use in case of a rare anaphylactic reaction following the administration of the vaccine.

If Guillain-Barré syndrome occurred within 6 weeks of receipt of prior vaccine containing tetanus toxoid, the decision to give any vaccine containing tetanus toxoid, including Repevax, should be based on careful consideration of the potential benefits and possible risks.

Repevax should not be administered to individuals with a progressive or unstable neurological disorder, uncontrolled epilepsy or progressive encephalopathy until a treatment regimen has been established and the condition has stabilized.

The rates and severity of adverse events in recipients of tetanus toxoid antigen are influenced by the number of prior doses and level of pre-existing antitoxins.

The immunogenicity of the vaccine could be reduced by immunosuppressive treatment or immunodeficiency. It is recommended to postpone the vaccination until the end of such disease or treatment if practical. Nevertheless, vaccination of HIV infected persons or persons with chronic immunodeficiency, such as AIDS, is recommended even if the antibody response might be limited.

Administration precautions

Do not administer by intravascular or intradermal injection.

Intramuscular injections should be given with care in patients on anticoagulant therapy or suffering from coagulation disorders because of the risk of haemorrhage. In these situations and following official recommendations the administration of Repevax by deep subcutaneous injection may be considered, although there is a risk of increased local reactions.

Syncope (fainting) can occur following, or even before, administration of injectable vaccines, including Repevax. Procedures should be in place to prevent falling injury and manage syncopal reactions.

Other considerations

As with any vaccine, a protective immune response may not be elicited in all vaccines (see section 5.1).

A persistent nodule at the site of injection may occur with all adsorbed vaccines, particularly if administered into the superficial layers of the subcutaneous tissue.

Traceability

In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.

Excipients with known effects

Repevax contains 1.01 milligram of alcohol (ethanol) in each 0.5 mL dose. The small amount of alcohol in this medicine will not have any noticeable effects.

**4.5 Interaction with other medicinal products and other forms of interaction**

Repevax may be administered concomitantly with a dose of inactivated influenza vaccine, based on the results of a clinical trial conducted in persons 60 years of age and older.

Repevax may be administered concomitantly with a dose of hepatitis B vaccine.

Repevax may be administered concurrently with a dose of recombinant Human Papillomavirus vaccine with no significant interference with antibody response to any of the components of either vaccine. However, a trend of lower anti-HPV GMTs was observed in the concomitant group. The clinical significance of this observation is not known. This is based on the results from a clinical trial in which Repevax was administered concomitantly with the first dose of Gardasil (see section 4.8).

Separate limbs must be used for the site of injection. Interaction studies have not been carried out with other vaccines, biological products or therapeutic medications. However, in accordance with commonly accepted immunization guidelines, since Repevax is an inactivated product it may be administered concomitantly with other vaccines or immunoglobulins at separate injection sites.

In the case of immunosuppressive therapy please refer to Section 4.4.

**4.6 Fertility, pregnancy and lactation**

Pregnancy

Repevax can be used during the second or third trimester of pregnancy in accordance with official recommendations (see section 4.2).

Safety data from 4 randomized controlled trials (310 pregnancy outcomes), 1 prospective observational study (546 pregnancy outcomes), 5 retrospective observational studies (124,810 pregnancy outcomes), and from passive surveillance of women who received Repevax or COVAXiS (Tdap; containing the same amounts of tetanus, diphtheria and pertussis antigens as Repevax ) during the second or third trimester have shown no vaccine-related adverse effect on pregnancy or on the health of the fetus/newborn child. As with other inactivated vaccines, it is not expected that vaccination with Repevax during any trimester would harm the fetus.

Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/fetal development, parturition or postnatal development.

For information on immune responses to vaccination during pregnancy and its effectiveness at preventing pertussis in infants, see section 5.1.

Breastfeeding

The effect of administration of Repevax during lactation has not been assessed. Nevertheless, as Repevax contains toxoids or inactivated antigens, no risk to the breastfed infant should be expected. The benefits versus the risk of administering Repevax to breastfeeding women should be evaluated by the health-care providers.

Fertility

Repevax has not been evaluated in fertility studies.

**4.7 Effects on ability to drive and use machines**

No traffic warning.

No studies on the effects on the ability to drive or use machines have been performed. Repevax has no or negligible influence on the ability to drive and use machines.

**4.8 Undesirable effects**

Summary of the safety profile

In clinical trials Repevax was given to a total of 1,384 persons including 390 children 3 through 6 years of age and 994 adolescent and adults. Most commonly reported reactions following vaccination included local reactions at the injection site (pain, redness and swelling). These signs and symptoms usually were mild in intensity and occurred within 48 hours following vaccination (Adverse Events have been observed within 24 hours and 7 days following vaccination in children 3 through 6 years). They all resolved without sequelae.

There was a trend for higher rates of local and systemic reactions in adolescents than in adults. In both age groups, injection site pain was the most common adverse reaction.
Late-onset local adverse reactions (i.e. a local adverse reaction which had an onset or increase in severity 3 to 14 days post-immunization), such as injection site pain, erythema and swelling occurred in less than 1.2%. Most of the reported adverse reactions occurred within 24 hours after the vaccination.

In a clinical trial of 843 healthy adolescent males and females 11-17 years of age, administration of the first dose of Gardasil concomitantly with Repevax showed that there was more injection-site swelling and headache reported following concomitant administration. The differences observed were < 10% and in the majority of subjects, the adverse events were reported as mild to moderate in intensity.

Tabulated list of adverse reactions

Adverse reactions are ranked under headings of frequency using the following convention:

Very common (≥1/10)
Common (≥1/100 to <1/10)
Uncommon (≥1/1,000 to <1/100)
Rare (≥1/10,000 to <1/1,000)
Very rare (<1/10,000), including individual cases
Not known cannot be estimated from the available data

Table 1 presents adverse reactions observed in clinical trials and also includes additionaladverse events which have been spontaneously reported during the post-marketing use of Repevax worldwide. Adverse events in children were collected from clinical trials conducted in 3 to 5 years of age and 5 to 6 years of age. The highest frequency from either study is presented. Because post-marketing adverse events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to vaccine exposure. Therefore, the frequency category “Not known” is assigned to these adverse events.

Table 1: Adverse events from clinical trials and worldwide post marketing experience

| **System Organ Class** | **Frequency** | **Children 3 through 6 years** | **Adolescents and Adults** |
| --- | --- | --- | --- |
| Blood and lymphatic system disorders | Not known | Lymphadenopathy\*  |
| Immune system disorders | Not known | Anaphylactic reactions, such as urticaria, face oedema and dyspnea\* |
| Nervous system disorders | Very common |  | Headache |
| Common | Headache |  |
| Not known | Convulsions, Vasovagal Syncope, Guillain Barré syndrome, Facial Palsy, Myelitis, Brachial Neuritis, Transient paresthesia/hypoesthesia of vaccinated limb, Dizziness\* |
| Gastrointestinal disorders | Very common | Diarrhoea | Nausea |
| Common | Vomiting,Nausea | Diarrhoea, Vomiting |
|  | Not known | Abdominal pain |
| Skin and subcutaneous system disorders | Common | Rash |  |
| Musculoskeletal and connective tissue disorders | Very common |  | Arthralgia/joint swelling, Myalgia |
| Common | Arthralgia/joint swelling |  |
| Not known | Pain in vaccinated limb\* |
| General disorders and administration site conditions | Very common | Fatigue/Asthenia,Fever†  | Fatigue/Asthenia, Chills |
| Injection site pain, Injection site swelling,Injection site erythema |
| Common | Irritability, Injection site dermatitis, Injection site bruising, Injection site pruritus | Fever† |
| Not known | Malaise§, Pallor\*, Extensive limb swelling‡, Injection site induration\* |

\* Post marketing adverse events

† Fever was measured as temperature ≥37.5°C in Children groups and measured as temperature ≥38°C in Adolescents and Adults group

‡ See section c)

§ was observed at a frequency of very common in adolescents and adults, in studies with COVAXiS (Tdap component of Repevax; containing the same amounts of diphtheria, tetanus and pertussis antigens)

Description of selected adverse reactions

Extensive limb swelling which may extend from the injection site beyond one or both joints and is frequently associated with erythema, and sometimes with blisters has been reported following administration of Repevax. The majority of these reactions appeared within 48 hours of vaccination and spontaneously resolved over an average of 4 days without sequelae.

The risk appears to be dependent on the number of prior doses of d/DTaP vaccine, with a greater risk following the 4th and 5th doses.

Paediatric population

The safety profile of Repevax in 390 children 3 to 6 years of age as presented in Table 1 is derived from two clinical studies:

* In a clinical study, 240 children were primed at 3, 5 and 12 months of age with a DTaP vaccine with no additional dose in the second year of life. These children received Repevax at 5 to 6 years of age.
* 150 children primed at 2, 3, and 4 months of age with a DTwP vaccine (with no additional dose in the second year of life) received Repevax at 3 to 5 years of age.

In both studies the rates of most systemic adverse events within 7 to 10 days following vaccination were less than 10%. Only fever (≥37.5°C) and fatigue were reported in more than 10 % of subjects 3 to 6 years of age. In addition, irritability was reported in more than 10% of subjects 3 to 5 years of age. (See Table 1).

Transient severe swelling of the injected upper arm was reported in <1% of children aged 5 to 6 years.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:

Lægemiddelstyrelsen

Axel Heides Gade 1

DK-2300 København S

Website: www.meldenbivirkning.dk

**4.9 Overdose**

Not applicable.

**4.10 Legal status**

B

**5. PHARMACOLOGICAL PROPERTIES**

**5.1 Pharmacodynamic properties**

Pharmacotherapeutic group: Bacterial and viral vaccines combined. Vaccine against diphtheria, tetanus, pertussis and poliomyelitis, ATC-Code: J07CA02

Clinical trials

The immune responses of children 3 to 6 years of age, adolescents and adults one-month after vaccination with Repevax are shown in the table below.

Table 2: Immune responses 4 weeks after vaccination with Repevax

| **Antibody** | **Criteria** | **Children** **3-5 years old1****(n = 148)** | **Children 5-6 years old2  (n = 240)** | **Adults and Adolescents3****(n = 994)** |
| --- | --- | --- | --- | --- |
| **Diphtheria** (SN, IU/mL) | 0.1  | 100% | 99.4% | 92.8% |
| **Tetanus** (ELISA, IU/mL or EU/mL)4 | 0.1  | 100% | 99.5% | 100% |
| **Pertussis** (ELISA, EU/mL) **Pertussis Toxoid**  **Filamentous Haemagglutinin**  **Pertactin**  **Fimbriae Types 2 and 3**  | 55  | 99.3%99.3%100%100% | 91.2%99.1%100%99.5% | 99.7%99.9%99.6%99.8% |
| **IPV** (SN, titre) |  |  |  |  |
| **Type 1****Type 2** **Type 3** | ≥ 1:8 | 100%100%100% | 100%100%100% | 99.9%100%100% |

ELISA: Enzyme Linked Immunoassay; EU: ELISA units; IPV: inactivated polio vaccine; IU: international units; n: number of participants who received REPEVAX; SN: seroneutralisation.

1 Studies U01-Td5I-303 and U02-Td5I-402 were conducted in UK with children previously primed with DTwP and OPV at 2, 3 and 4 months of age. U01-Td5I-303 enrolled children 3.5-5 years of age. U02-Td5I-402 enrolled children 3-3.5 years of age.

2 The Sweden 5.5 study was conducted in Swedish with children 5-6 years of age previously primed with DTaP and IPV at 3, 5, and 12 months of age.

3 Studies TD9707 and TD9809 were conducted in Canada. TD9707 enrolled adolescents 11-17 years of age and adults 18-64 years of age. Study TD9809 enrolled adolescents 11-14 years of age.

4. Tetanus units differed by the testing lab. Results were in IU/mL for the Sweden 5.5 study and in EU/mL for the other studies.

5. Antibody levels of ≥5 EU/mL were postulated as possible surrogate markers for protection against pertussis by Storsaeter J et al. Vaccine 1998;16:1907-16.

The use of Repevax in children aged 3 to 6 years is based upon studies in which Repevax was given as the fourth dose (first booster) of diphtheria, tetanus, pertussis and poliomyelitis vaccines. Robust immune responses were observed following a single dose of Repevax in children primed with either a whole cell pertussis vaccine (DTwP) and OPV (UK studies; ages 3-5 years) or an acellular pertussis vaccine (DTaP) and IPV (Sweden study; ages 5-6 years) during infancy.

The safety and immunogenicity of Repevax in adults and adolescents was shown to be comparable to that observed with a single booster dose of Td adsorbed or Td Polio adsorbed vaccines containing a similar amount of tetanus and diphtheria toxoids and inactivated poliovirus types 1, 2 and 3. The lower response to diphtheria toxoid in adults probably reflected the inclusion of some participants with an uncertain or incomplete immunization history.

Serological correlates of protection against pertussis have not been established. On comparison with data from the Sweden I pertussis efficacy trials conducted between 1992 and 1996, where primary immunization with Sanofi Pasteur’s acellular pertussis infant DTaP formulation confirmed a protective efficacy of 85% against pertussis disease, it is considered that REPEVAX had elicited protective immune responses in children, adolescents, and adults in clinical trials.

*Antibody persistence*

Pivotal studies conducted with COVAXiS provide serology follow-up data at 3, 5 and 10 years, in individuals previously immunized with a single booster dose of COVAXiS. Persistence of seroprotection to diphtheria and tetanus, and seropositivity to pertussis is summarised in Table 3.

Table 3: Persistence of Seroprotection/Seropositivity Rates (%) in Children, Adolescents and Adults at 3-, 5- and 10- years following a dose of COVAXiS (Tdap component of Repevax) (PPI Population1)

|  | **Children** (4-6 years)2 | **Adolescents** (11-17 years)3 | **Adults**(18-64 years)3 |
| --- | --- | --- | --- |
| Time since COVAXiS dose | **5 years**  | **3 years**  | **5 years**  | **10 years**  | **3 years**  | **5 years**  | **10 years**  |
|  Participants | N=128-150 | N=300 | N=204-206 | N=28-39 | N=292 | N=237-238 | N=120-136 |
| Antibody | % Seroprotection/Seropositivity |
| Diphtheria(SN, IU/mL) | ≥ 0.1  | 86.0 | 97.0 | 95.1 | 94.9 | 81.2 | 81.1 | 84.6 |
| ≥ 0.01  | 100 | 100 | 100 | 100 | 95.2 | 93.7 | 99.3 |
| Tetanus(ELISA, IU/mL) | ≥ 0.1  | 97.3 | 100 | 100 | 100 | 99.0 | 97.1 | 100 |
| Pertussis(ELISA, EU/mL) | Sero-positivity4 |  |  |  |  |  |  |  |
| PT | 63.3 | 97.3 | 85.4 | 82.1 | 94.2 | 89.1 | 85.8 |
| FHA | 97.3 | 100 | 99.5 | 100 | 99.3 | 100 | 100 |
| PRN | 95.3 | 99.7 | 98.5 | 100 | 98.6 | 97.1 | 99.3 |
| FIM | 98.7 | 98.3 | 99.5 | 100 | 93.5 | 99.6 | 98.5 |

ELISA: Enzyme Linked Immunoassay; EU: ELISA units; IU: international units; N: number of participants with

available data; PPI: per protocol immunogenicity; SN: seroneutralisation;

1 Eligible participants for whom immunogenicity data were available for at least one antibody at the specified

time-point.

2 Study Td508 was conducted in Canada with children 4-6 years of age.

3 Study Td506 was conducted in the United States with adolescents 11-17 years of age and adults 18-64 years of age.

4 Percentage of participants with antibodies ≥ 5 EU/mL for PT, ≥ 3 for FHA and PRN, and ≥ 17 EU/mL for FIM for the 3 year follow-up; ≥ 4 EU/mL for PT, PRN and FIM, and ≥ 3 EU/mL for FHA for the 5-year and 10-year follow-up

Follow-up studies conducted with Repevax provide serology data at 1, 3, 5 and 10 years in individuals previously immunized with a single booster dose of Repevax. Persistence of seroprotection to diphtheria and tetanus, seropositivity to pertussis and seroprotective antibody levels (≥1:8 dilution) for each poliovirus (types 1, 2 and 3) are summarized in Table 4.

**Table 4: Persistence of Seroprotection/Seropositivity Rates (%) in Children, Adolescents and Adults at 1-, 3-, 5- and 10- years following a dose of Repevax (ITT Population1)**

|  | **Children** (3.5-5 years)2 | **Adolescents** (11-17 years)2 | **Adults**(18-64 years)2 |
| --- | --- | --- | --- |
| **Time since REPEVAX dose** | **1** **year** | **3 years** | **5 years** | **1 year** | **3** **years** | **5** **years** | **10 years** | **1** **year** | **3** **years** | **5** **years** | **10 years** |
| **Participants** | N=36-37 | N=36 | N=38-48 | N=64 | N=117 | N=108 | N=97-107 | N=32 | N=135-136 | N=127 | N=67-79 |
| **Antibody** | **% Seroprotection/Seropositivity** |
| **Diphtheria**(SN, IU/mL) | ≥ 0.1  | 89.2 | 72.2 | 75.0 | 71.9 | 85.2 | 77.1 | 68.5 | 62.5 | 55.6 | 35.2 | 32.9 |
| ≥ 0.01  | 100 | 100 | 100 | 100 | 99.1 | 96.2 | 99.1 | 90.6 | 91.9 | 79.2 | 84.8 |
| **Tetanus**(ELISA, IU/mL) | ≥ 0.1  | 100 | 100 | 100 | 100 | 100 | 100 | 97.2 | 100 | 97.8 | 98.4 | 93.7 |
| **Pertussis**(ELISA, EU/mL) | Sero-positivity3,4 |  |  |  |  |  |  |  |  |  |  |  |
| **PT** | 89.2 | 61.1 | 55.3 | 98.4 | 96.6 | 99.1 | 87.6 | 100 | 97.1 | 97.6 | 91.0 |
| **FHA** | 100 | 94.4 | 100 | 100 | 99.1 | 99.1 | 98.1 | 100 | 100 | 100 | 100 |
| **PRN** | 97.3 | 91.7 | 95.7 | 100 | 99.1 | 100 | 88.8 | 100 | 99.3 | 98.4 | 93.7 |
| **FIM** | 100 | 100 | 95.7 | 98.4 | 98.3 | 98.1 | 100 | 93.8 | 94.1 | 93.7 | 98.7 |
| **IPV**(SN, titre) | ≥ 1:8  |  |  |  |  |  |  |  |  |  |  |  |
| **Type 1** | 100 | 100 | 97.9 | 98.4 | 100 | 100 | NA | 100 | 100 | 100 | NA |
| **Type 2** | 100 | 100 | 100 | 100 | 100 | 100 | NA | 100 | 100 | 100 | NA |
| **Type 3** | 100 | 97.2 | 95.7 | 98.4 | 100 | 98.2 | NA | 100 | 100 | 100 | NA |

ELISA: Enzyme Linked Immunoassay; EU: ELISA units; IPV: inactivated polio vaccine; ITT: intention to treat; IU: international units; N: number of participants with available data; NA: not analysed; SN: seroneutralisation.

1 ITT population: Study U01-Td5I-303-LT: Eligible participants for whom immunogenicity data were available for at least one antibody at the specified time point and at year 5. Study TD9707-LT: Eligible participants for whom immunogenicity data were available for at least one antibody at the specified time point.

2 Study U01-Td5I-303-LT conducted in UK with children 3.5-5 years of age; Study TD9707-LT conducted in Canada with adolescents 11-17 years of age and adults 18-64 years of age.

3 For U01-Td5I-303-LT: percentage of participants with antibodies ≥ 5 EU/mL for PT, ≥ 3 for FHA and ≥ 4 for PRN and for FIM for the 1-year follow-up; ≥ 4 EU/mL for PT, FIM and PRN, and ≥ 3 EU/mL for FHA for the 3-year and 5-year follow-up.

4 For TD9707-LT: percentage of participants with antibodies ≥ 5 EU/mL for PT, ≥ 3 EU/mL for FHA and PRN, and ≥ 17 EU/mL for FIM for all time points except 10 years; ≥ 4 EU/mL for PT, FIM and PRN and ≥ 3 EU/mL for FHA for 10-year follow-up.

*Immunogenicity following repeat vaccination*

The immunogenicity of COVAXiS following repeat vaccination 10 years after a previous dose of COVAXiS or Repevax, has been evaluated. One month post-vaccination ≥ 98.5% of study participants achieved seroprotective antibody levels (≥ 0.1 IU/mL) for diphtheria and tetanus, and ≥ 84% achieved booster responses to the pertussis antigens. (A pertussis booster response was defined as a post-vaccination antibody concentration ≥ 4 times the LLOQ (Lower Limit Of Quantification) if the pre-vaccination level was < LLOQ; ≥ 4 times the pre-vaccination level if that was ≥ LLOQ but < 4 times LLOQ; or ≥ 2 times the pre-vaccination level if that was ≥ 4 times the LLOQ).

Based on the serology follow-up and repeat vaccination data, Repevax can be used instead of a dT vaccine or dT-IPV vaccine to boost immunity to pertussis in addition diphtheria, tetanus and polio.

*Immunogenicity in naïve subjects*

After administration of one dose of Repevax to 330 adults ≥40 years of age that had not received any diphtheria- and tetanus-containing vaccine in the past 20 years:

* ≥95.8% of adults were seropositive (≥ 5 IU/mL) for antibodies to all vaccine-containing pertussis antigens,
* 82.4% and 92.7% were seroprotected against diphtheria at a threshold ≥0.1 and ≥0.01 IU/mL, respectively,
* 98.5% and 99.7% were seroprotected against tetanus at a threshold ≥0.1 and ≥0.01 IU/mL, respectively,
* and ≥98.8% were seroprotected against polio (types 1, 2 and 3) at a threshold ≥1:8 dilution.

After administration of two additional doses of diphtheria- tetanus- and polio-containing vaccine to 316 subjects, one and six months after the first dose, the seroprotection rates against diphtheria were 94.6% and 100% (≥0.1 and ≥ 0.01 IU/mL, respectively), against tetanus 100% (≥0.1 IU/mL), and against polio (types 1, 2 and 3) 100% (≥1:8 dilution) (see Table 4).

Table 5: Serological immune status (seroprotection/seroresponse rates and GMC/GMT) before vaccination and after each dose of a 3 dose-vaccination schedule including REPEVAX® (Dose 1) followed by 2 doses of REVAXIS® 1 and 6 months later (Dose 2 and 3) in subjects vaccinated according to protocol (FAS)

| **Antigen**  | **Criteria** | **Pre-vaccination** | **Post-dose 1 REPEVAX®** | **Post-dose 2 REVAXIS®** | **Post-dose 3REVAXIS®** |
| --- | --- | --- | --- | --- | --- |
|  |  | N=330 | N=330 | N=325 | N=316 |
| **Diphtheria**  | GMC | 0.059 | 0.813 | 1.373 | 1.489 |
| **(SN, IU/mL)** | 95%CI | [0.046; 0.077] | [0.624; 1.059] | [1.100; 1.715] | [1.262; 1.757] |
|  | ≥0.1  | 44.5% | 82.4% | 90.5% | 94.6% |
|  | 95%CI | [39.1; 50.1] | [77.9; 86.4] | [86.7; 93.4] | [91.5; 96.8] |
|  | ≥0.01  | 72.4% | 92.7% | 96.0% | 100% |
|  | 95%CI | [67.3; 77.2] | [89.4; 95.3] | [93.3; 97.9] | [98.8; 100] |
| **Tetanus**  | GMC | 0.48 | 6.82 | 7.60 | 5.46 |
| **(ELISA, IU/mL)** | 95%CI | [0.39;0.60] | [5.92;7.87] | [6.77;8.52] | [5.01;5.96] |
|  | ≥0.1  | 81.2% | 98.5% | 100% | 100% |
|  | 95%CI | [76.6; 85.3] | [96.5; 99.5] | [98.9; 100] | [98.8; 100] |
|  | ≥0.01  | 92.4% | 99.7% | 100% | 100% |
|  | 95%CI | [89.0; 95.0] | [98.3; 100] | [98.9; 100] | [98.8; 100] |
| **Poliomyelitis (SN, 1/dil)** |
| **Type 1** | GMT | 162.6 | 2869.0 | 2320.2 | 1601.9 |
|  | 95%CI | [133.6; 198.0] | [2432.9; 3383.4] | [2010.9; 2677.0] | [1425.4; 1800.3] |
|  | ≥8 | 93.3% | 99.4% | 100% | 100% |
|  | 95%CI | [90.1; 95.8] | [97.8; 99.9] | [98.9; 100] | [98.8; 100] |
| **Type 2** | GMT | 164.5 | 3829.7 | 3256.0 | 2107.2 |
|  | 95%CI | [137.6;196.8] | [3258.5;4501.1] | [2818.2;3761.7] | [1855.7;2392.8] |
|  | ≥8 | 95.5% | 100% | 100% | 100% |
|  | 95%CI | [92.6; 97.4] | [98.9; 100] | [98.9; 100] | [98.8; 100] |
| **Type 3** | GMT | 69.0 | 5011.4 | 3615.6 | 2125.8 |
|  | 95%CI | [56.9; 83.6] | [4177.4; 6012.0] | [3100.5; 4216.4] | [1875.5; 2409.6] |
|  | ≥8 | 89.1% | 98.8% | 99.7% | 100% |
|  | 95%CI | [85.2; 92.2] | [96.9; 99.7] | [98.3; 100] | [98.8; 100] |
| **Pertussis (ELISA, EU/mL)** |
| **PT**  | GMC  | 7.7 | 41.3 |  |  |
|  | 95%CI | [6.8; 8.7] | [36.7; 46.5] |  |  |
|  | ≥5  | - | 96.3% | - | - |
|  | 95%CI |  | [93.6; 98.1] |  |  |
| **FHA** | GMC  | 28.5 | 186.7 |  |  |
|  | 95%CI | [25.5; 31.8] | [169.6; 205.6] |  |  |
|  | ≥5  | - | 100% | - | - |
|  | 95%CI |  | [98.9; 100] |  |  |
| **PRN** | GMC  | 7.7 | 328.6 |  |  |
|  | 95%CI | [6.7; 8.9] | [273.0; 395.6] |  |  |
|  | ≥5  | - | 99.4% | - | - |
|  | 95%CI |  | [97.8; 99.9] |  |  |
| **FIM** | GMC  | 6.1 | 149.6 |  |  |
|  | 95%CI | [5.2; 7.1] | [123.6; 181.0] |  |  |
|  | ≥5  | - | 95.8% | - | - |
|  | 95%CI |  |  [93.0; 97.7] |  |  |

GMC: Geometric mean of antibody concentrations; GMT: Geometric mean of antibody titres; CI: Confidence Interval; SN: seroneutralisation; ELISA: Enzyme Linked Immunoassay; dil: dilution

FAS: Full Analysis Set – includes all subjects who received the study vaccine dose and for whom the post-vaccination immunogenicity evaluation was available.

*Immunogenicity in pregnant women*

Pertussis antibody responses in pregnant women are generally similar to those in non-pregnant women. Vaccination during the second or third trimester of pregnancy is optimal for antibody transfer to the developing fetus.

*Immunogenicity against pertussis in infants (<3 months of age) born to women vaccinated during pregnancy*

Data from 2 published randomized controlled trials demonstrate higher pertussis antibody concentrations at birth and at 2 months of age, (ie, prior to the start of their primary vaccinations) in infants of women vaccinated with COVAXiS during pregnancy compared with infants of women not vaccinated against pertussis during pregnancy.

In the first study, 33 pregnant women received COVAXiS and 15 received saline placebo at 30 to 32 weeks gestation. The geometric mean concentrations (GMC) in EU/mL for the anti-pertussis antibodies to the PT, FHA, PRN, and FIM antigens in infants of vaccinated women were, respectively, 68.8, 234.2, 226.8, and 1867.0 at birth, and 20.6, 99.1, 75.7, and 510.4 at 2 months of age. In the control-group infants, the corresponding GMCs were 14.0, 25.1, 14.4, and 48.5 at birth, and 5.3, 6.6, 5.2, and 12.0 at 2 months. The GMC ratios (COVAXiS/control group) were 4.9, 9.3, 15.8, and 38.5 at birth, and 3.9, 15.0, 14.6, and 42.5 at 2 months.

In the second study, 134 pregnant women received COVAXiS and 138 received a tetanus and diphtheria control vaccine at a mean gestational age of 34.5 weeks. The GMCs (EU/mL) for the anti-pertussis antibodies to the PT, FHA, PRN, and FIM antigens in infants of vaccinated women were, respectively, 54.2, 184.2, 294.1, and 939.6 at birth, and 14.1, 51.0, 76.8, and 220.0 at 2 months of age. In the control-group infants, the corresponding GMCs were 9.5, 21.4, 11.2, and 31.5 at birth, and 3.6, 6.1, 4.4, and 9.0 at 2 months. The GMC ratios (COVAXiS/control group) were 5.7, 8.6, 26.3, and 29.8 at birth, and 3.9, 8.4, 17.5, and 24.4 at 2 months.

These higher antibody concentrations should provide passive immunity against pertussis for the infant during the first 2 to 3 months of life, as has been shown by observational effectiveness studies.

*Immunogenicity in infants and toddlers born to women vaccinated during pregnancy*

For infants of women vaccinated with Repevax or COVAXiS during pregnancy, the immunogenicity of routine infant vaccination was assessed in several published studies. Data on the infant response to pertussis and non-pertussis antigens were evaluated during the first year of life.

Maternal antibodies derived after Repevax or COVAXiS vaccination in pregnancy may be associated with blunting of the infant immune response to active immunization against pertussis. Based on current epidemiological studies, this blunting may not have clinical relevance.

Data from several studies did not show any clinically relevant blunting from vaccination in pregnancy with Repevax or COVAXiS and the infants’ or toddlers’ responses to diphtheria, tetanus, *Haemophilus* *influenzae* type b, inactivated poliovirus, or pneumococcal antigens.

*Effectiveness against pertussis in infants born to women vaccinated during pregnancy*

The vaccine effectiveness in the first 2-3 months of life for infants born to women vaccinated against pertussis during the third trimester of pregnancy has been evaluated in 3 observational studies. The overall effectiveness is > 90%.

**Table 6: Vaccine effectiveness (VE) against pertussis disease in young infants born to mothers vaccinated during pregnancy with REPEVAX or COVAXiS in 3 retrospective studies.**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Location** | **Vaccine** | **VE (95% CI)** | **VE estimation method** | **Infant follow-up period** |
| **UK** | REPEVAX | 93% (81, 97) | unmatched case-control | 2 months |
| **US** | COVAXiS\* | 91.4% (19.5, 99.1) | cohort regression model | 2 months |
| **UK** | REPEVAX | 93% (89, 95) | screening (case-coverage) | 3 months |
| \* Approximately 99% of women were vaccinated with COVAXiS |

**5.2 Pharmacokinetic properties**

Evaluation of pharmacokinetic properties is not required for vaccines.

**5.3 Preclinical safety data**

Non-clinical data revealed no special hazard for humans based on conventional studies of repeated doses toxicity.

**6. PHARMACEUTICAL PARTICULARS**

**6.1 List of excipients**

Phenoxyethanol
Ethanol
Polysorbate 80
Water for injections

For adjuvant see section 2

**6.2 Incompatibilities**

In the absence of compatibility studies, Repevax must not be mixed with other medicinal products.

**6.3 Shelf life**

4 years.

**6.4 Special precautions for storage**

Store in a refrigerator at 2°C to 8°C.

Do not freeze. Discard the vaccine if it has been frozen.

Keep the container in the outer carton in order to protect from light.

**6.5 Nature and contents of container**

0.5 mL of suspension in pre-filled syringe (glass) with a plunger stopper (chlorobromobutyl or bromobutyl or chlorobutyl elastomer), without attached needle, with a tip-cap (chlorobromobutyl elastomer or synthetic isoprene-bromobutyl elastomer) - pack size of 1, 10 or 20.

0.5 mL of suspension in pre-filled syringe (glass) with a plunger stopper (chlorobromobutyl or bromobutyl or chlorobutyl elastomer), without attached needle, with a tip-cap (chlorobromobutyl elastomer or synthetic isoprene-bromobutyl elastomer) and 1 or 2 separate needles - pack size of 1 or 10.

0.5 mL of suspension in pre-filled syringe (glass) with a plunger stopper (chlorobromobutyl or bromobutyl or chlorobutyl elastomer) with attached needle and needle guard (translucent polypropylene rigid safeshield and polyisoprene) - pack size of 1, 10 or 20.

Not all pack sizes may be marketed.

**6.6 Special precautions for disposal and other handling**

Instructions for use

Parenteral products should be inspected visually for extraneous particulate matter and/or discoloration prior to administration. In the event of either being observed, discard the medicinal product.

The normal appearance of the vaccine is a uniform cloudy, white suspension which may sediment during storage. Shake the prefilled syringe well to uniformly distribute the suspension before administering the vaccine.

For needle free syringes, the needle should be pushed firmly on to the end of the prefilled syringe and rotated through 90 degrees.

Disposal

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

Needles should not be recapped.

**7. MARKETING AUTHORISATION HOLDER**

Sanofi Winthrop Industrie

82 Avenue Raspail

94250 Gentilly

Frankrig

**Representative**

Sanofi A/S

Lyngbyvej 2

2100 København Ø

**8. MARKETING AUTHORISATION NUMBER(S)**

33442

**9. DATE OF FIRST AUTHORISATION**

6 March 2003

**10. DATE OF REVISION OF THE TEXT**

14 January 2025